Research advances in the application of methylprednisolone in the treatment of acute spinal cord injury.
10.3881/j.issn.1000-503X.2014.06.023
- Author:
Xiang-Yi KONG
1
;
Jun GAO
1
;
Yi YANG
1
;
Yong-Ning LI
1
;
Wen-Bin MA
1
;
Bing XING
1
;
Ren-Zhi WANG
1
Author Information
1. Department of Neurosurgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- MeSH:
Clinical Trials as Topic;
Humans;
Methylprednisolone;
therapeutic use;
Neuroprotective Agents;
therapeutic use;
Spinal Cord Injuries;
drug therapy;
Treatment Outcome
- From:
Acta Academiae Medicinae Sinicae
2014;36(6):680-685
- CountryChina
- Language:English
-
Abstract:
Acute spinal cord injury(ASCI),mainly caused by traffic accidents and fall injuries,is a catastrophic event that can profoundly affect the trajectory of a patient's life. Debate continues over the medical management of ASCI,in particular the usefulness,dosage,and potential risks of methylprednisolone(MP). Although the results of American National Acute Spinal Cord Injury Study 2 and 3 trials led to the wide adoption of a high-dose MP regimen for ASCI patients,the reliabilities of their study methods and data were still questionable. Based on the currently available literature,we conclude that high-dose MP is no longer a recommended therapy for ASCI;however,due to the lack of effective treatment,it remains a useful option for this condition.
